1. Ministry of Health, Labour and Welfare, Risk Management Plan Guidance (Pharmaceutical Food Safety Bureau, Safety Division Notification No. 0411-1, Evaluation and Licensing Division Notification No. 0411-2, 2012, https://www.pmda.go.jp/files/000153333.pdf. Accessed 26 April 2021
2. ICH harmonised tripartite guideline, pharmacovigilance planning (E2E), 2004, https://database.ich.org/sites/default/files/E2E_Guideline.pdf. Accessed 26 April 2021.
3. European Medicine Agency, Guideline on good pharmacovigilance practices (GVP), Module V – Risk management systems (Rev 2), EMA/838713/2011 Rev 2*, 2016, https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-v-risk-management-systems-rev-2_en.pdf. Accessed 26 April 2021
4. Hirota S, Yamaguchi T. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: an analysis of safety specifications of Japan and European Union risk management plans. Pharmacoepidemiol Drug Saf. 2018;27:1231–8.
5. Postmarketing Studies and Clinical Trials-Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry, October 2019, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-studies-and-clinical-trials-implementation-section-505o3-federal-food-drug-and. Accessed 26 April 2021